Astellas-Maxygen Joint Venture Highlights Japan's Creative Alliances - BIO Asia Conference

TOKYO - Astellas, like most top-tier Japanese pharmaceutical companies, has been aggressive in its out-licensing in the past year, and its 2009 joint venture with Maxygen highlights how Japanese companies are using creative deals to stay competitive